Market Place
Sourcing Support
Inmune Bio To Report 2025 Financials And Corporate Update
24 Mar 2026 //
GLOBENEWSWIRE
Inmune Bio To Present Twice At 18th Annual CTAD Conference
18 Nov 2025 //
GLOBENEWSWIRE
Inmune Bio To Release Q3 2025 Financials And Corporate Update
23 Oct 2025 //
GLOBENEWSWIRE
INmune Bio Inc. Announces Q2 2025 Financial Results on August 7th
31 Jul 2025 //
GLOBENEWSWIRE
INmune Bio Reveals Phase 2 MINDFuL Trial Results at Conference
24 Jul 2025 //
GLOBENEWSWIRE
INmune Bio, Inc. Announces $19M Direct Offering on Nasdaq
27 Jun 2025 //
GLOBENEWSWIRE
INmune to Share MINDFuL Ph2 Alzheimer’s Data June 30
26 Jun 2025 //
GLOBENEWSWIRE
INmune Bio Presents Baseline Demographics of MINDFuL Study
01 Apr 2025 //
GLOBENEWSWIRE
INmune Bio to Report Q4 2024 Results on March 27, 2025
24 Mar 2025 //
GLOBENEWSWIRE
INmune Bio To Report Q3 2024 Results And Update
24 Oct 2024 //
GLOBENEWSWIRE
INmune Bio Completes Enrollment For Ph 2 Alzheimer`s Trial
30 Sep 2024 //
GLOBENEWSWIRE
INmune Bio Inc. to Present at the Baird 2024 Global Healthcare Conference
03 Sep 2024 //
GLOBENEWSWIRE
INmune Bio Reports Q2 2024 Results And Business Update
01 Aug 2024 //
GLOBENEWSWIRE
INmune Bio Reports XPro™ Effect On Synaptic Proteins In Alzheimer`s Study
29 Jul 2024 //
GLOBENEWSWIRE
INmune Bio To Report Q2 Results On August 1
25 Jul 2024 //
GLOBENEWSWIRE
INmune Bio Publishes INKmune™ Study In ImmunoTherapy Of Cancer Journal
23 Jul 2024 //
GLOBENEWSWIRE
INmune Completes Blinded Interim Analysis of Phase II Alzheimer’s Disease Trial
27 Jun 2024 //
GLOBENEWSWIRE
INmune Bio Inc. to Join Russell 3000® Index
30 May 2024 //
GLOBENEWSWIRE
INmune Bio Announces Q1 2024 Results And Business Update
09 May 2024 //
GLOBENEWSWIRE
INmune To Report Q1 2024 Results And Update On May 9
07 May 2024 //
GLOBENEWSWIRE
INmune Bio XPro™ Compassionate Use Update in Alzheimer`s
30 Apr 2024 //
GLOBENEWSWIRE
INmune Announces $9.7M Registered Direct Offering
25 Apr 2024 //
GLOBENEWSWIRE
INmune Bio Announces 24-Month Stability Valid of XPro™ for Phase III Readiness
23 Apr 2024 //
PRESS RELAESE
INmune Bio Announces 24-Month XPro Stability, Phase 3 Readiness Modeling
23 Apr 2024 //
GLOBENEWSWIRE
INmune $4.8M Direct With 20% Insider Participation
22 Apr 2024 //
GLOBENEWSWIRE
INmune Presents Data on INB03`s at AACR 2024
08 Apr 2024 //
GLOBENEWSWIRE
INmune Bio Inc. Announces Year End 23 Results and Provides a Q4 Business Update
28 Mar 2024 //
GLOBENEWSWIRE
INmune Bio Inc. to Report Fourth Quarter 2023 Financial Results
26 Mar 2024 //
GLOBENEWSWIRE
INmune Bio CSO and Co-Founder Mark Lowdell, Ph.D. Receives The ISCT
13 Mar 2024 //
GLOBENEWSWIRE
INmune Bio Reports EEG Improvement in Alzheimers Patients Treated with XPro„¢
05 Mar 2024 //
GLOBENEWSWIRE
INmune Bio to Participate in the Oppenheimer 34th Annual Conference
12 Feb 2024 //
GLOBENEWSWIRE
INmune Announces FDA Removal of Clinical Hold for Alzheimer™s Disease Program
30 Jan 2024 //
GLOBENEWSWIRE
INmune Bio Provides Update Regarding Global Alzheimer™s Phase II Trial
18 Dec 2023 //
GLOBENEWSWIRE
INmune Bio Receives EMA™s Authorization for Phase II Clinical Trial of XPro
27 Nov 2023 //
GLOBENEWSWIRE
INmune Announces Expansion of Phase II Clinical Trial for Alzheimer™s Disease
15 Nov 2023 //
GLOBENEWSWIRE
INmune Bio Announces Third Quarter 2023 Results and Provides Business Update
01 Nov 2023 //
GLOBENEWSWIRE
INmune Bio Inc. Presents Preclinical Data at SITC 2023
30 Oct 2023 //
GLOBENEWSWIRE
INmune Presents Data from Phase 1b Study Supporting the Use of XPro
17 Oct 2023 //
GLOBENEWSWIRE
INmune Bio Inc. to Report Third Quarter 2023 Financial Results
16 Oct 2023 //
GLOBENEWSWIRE
INmune Bio Inc. to Present at Baird Global Healthcare Conference
07 Sep 2023 //
GLOBENEWSWIRE
INmune Announces Approval of Clinical Trial Application by the U.K. Medicines
05 Sep 2023 //
GLOBENEWSWIRE
INmune Bio Announces Second Quarter 2023 Results and Provides Business Update
07 Aug 2023 //
GLOBENEWSWIRE
INmune Bio Inc. to Present at the BTIG Virtual Biotechnology Conference
01 Aug 2023 //
GLOBENEWSWIRE
INmune Bio, Inc. to Report Second Quarter 2023 Financial Results
31 Jul 2023 //
GLOBENEWSWIRE
INmune to Deliver Keynote Talk at 5th World Aging and Rejuvenation Conference.
12 Jul 2023 //
GLOBENEWSWIRE
INmune Announces Data Presented at the 16th European Meeting on Glial Cells
10 Jul 2023 //
GLOBENEWSWIRE
INmune Bio Inc. CSO r, Mark Lowdell, Ph.D. to Present Plenary Talk
24 May 2023 //
GLOBENEWSWIRE
INmune Bio Inc. Announces 1Q 2023 Results and Provides Business Update
03 May 2023 //
GLOBENEWSWIRE
INmune Bio, Inc. to Report First Quarter 2023 Financial Results
24 Apr 2023 //
GLOBENEWSWIRE
INmune to Present Data at 2023 AACR Showing Improved Outcomes with INB03
11 Apr 2023 //
GLOBENEWSWIRE
INmune Bio, Inc. Announces 2022 Results and Provides Business Update
02 Mar 2023 //
GLOBENEWSWIRE
INmune Bio, Inc. to Report Fourth Quarter and Full-Year 2022 Results
21 Feb 2023 //
GLOBENEWSWIRE
INmune Bio, Inc. Receives Approximately $6.4 Million in R&D Rebates
08 Feb 2023 //
GLOBENEWSWIRE
INmune Announces Data That Support a Pioneering Approach to Treating DMD
25 Jan 2023 //
GLOBENEWSWIRE
INmune Bio, Virginia Commonwealth, & Barrow Neurological Receive Defense Funding
22 Dec 2022 //
GLOBENEWSWIRE
INmune Bio Data at ASH Highlight Innovative Natural Killer Cell Therapeutic
08 Dec 2022 //
GLOBENEWSWIRE
INmune Bio, Inc. Reports Combination Therapy with INB03™
06 Dec 2022 //
GLOBENEWSWIRE
INmune Bio Receives Health Canada “No Objection Letter” to Trial of XPro1595
14 Nov 2022 //
GLOBENEWSWIRE
INmune Bio Announces Third Quarter 2022 Results and Provides Business Update
02 Nov 2022 //
GLOBENEWSWIRE
